Literature DB >> 8957015

Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma.

S D Meriney1, S C Hulsizer, V A Lennon, A D Grinnell.   

Abstract

Barium currents through voltage-gated calcium (Ca2+) channels were studied in the small-cell lung carcinoma cell line NCI-H345 using patch clamp techniques. Pharmacological dissection of whole-cell barium currents revealed that 23% of the current was sensitive to nitrendipine, 35% to omega-conotoxin GVIA, and between 10 and 39% to omega-Aga-IVA. This implies that these cells express L-, N-, and P-type calcium channels. Only large cells expressed current that was sensitive to omega-Aga-IVA. The size dependency of this P-type channel expression may reflect the cell cycle stage. Cell-attached recordings revealed three unitary conductances: 5 to 6 pS, 10 to 12 pS, and 20 to 23 pS. The largest conductance channel (20-23 pS) was sensitive to Bay K 8644 and is presumed to represent L-type calcium channels. The frequency of observing the medium conductance channel (10-12 pS) was reduced by exposure to omega-conotoxin GVIA and may represent N-type channels. Incubation of cells with Lambert-Eaton myasthenic syndrome IgG for 24 to 48 hours removed up to 71% of the whole-cell current. Incubation with control human IgG (normal or myasthenia gravis) had no effect. Lambert-Eaton myasthenic syndrome IgG did not selectively target one "presynaptic" type of calcium channel, but rather appeared to target many of the calcium channel types that are expressed on small-cell lung carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957015     DOI: 10.1002/ana.410400510

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  23 in total

Review 1.  Immunological mechanisms in paraneoplastic peripheral neuropathy.

Authors:  J C Antoine
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

Review 2.  Neuronal central nervous system syndromes probably mediated by autoantibodies.

Authors:  Aude Chefdeville; Jérôme Honnorat; Christiane S Hampe; Virginie Desestret
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

3.  Neurological channelopathies.

Authors:  M R Rose
Journal:  BMJ       Date:  1998-04-11

Review 4.  Lambert-Eaton myasthenic syndrome.

Authors:  U Seneviratne; R de Silva
Journal:  Postgrad Med J       Date:  1999-09       Impact factor: 2.401

Review 5.  Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.

Authors:  Stephen D Meriney; Tyler B Tarr; Kristine S Ojala; Man Wu; Yizhi Li; David Lacomis; Adolfo Garcia-Ocaña; Mary Liang; Guillermo Valdomir; Peter Wipf
Journal:  Ann N Y Acad Sci       Date:  2017-11-10       Impact factor: 5.691

6.  Lambert-Eaton antibodies inhibit Ca2+ currents but paradoxically increase exocytosis during stimulus trains in bovine adrenal chromaffin cells.

Authors:  K L Engisch; M M Rich; N Cook; M C Nowycky
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

7.  Low level anti-Hu reactivity: A risk marker for small cell lung cancer?

Authors:  Jeffrey A Tsou; Meleeneh Kazarian; Ankur Patel; Janice S Galler; Ite A Laird-Offringa; Catherine L Carpenter; Stephanie J London
Journal:  Cancer Detect Prev       Date:  2008-12-12

8.  Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in vivo.

Authors:  Yaping Joyce Liao; Parsa Safa; Yi-Ren Chen; Raymond A Sobel; Edward S Boyden; Richard W Tsien
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-13       Impact factor: 11.205

Review 9.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

10.  Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.

Authors:  Tyler B Tarr; David Lacomis; Stephen W Reddel; Mary Liang; Guillermo Valdomir; Michael Frasso; Peter Wipf; Stephen D Meriney
Journal:  J Physiol       Date:  2014-07-11       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.